The use of PSA as biomarker in nutritional intervention studies of prostate cancer

Chemico-Biological Interactions

Volumn 171, Issue 2, 2008, Pages 204-211

  van Weerden, Wytske M ^a   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chemoprevention; Prostate cancer; PSA; Xenograft models

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; BIOLOGICAL MARKER; CAROTENOID; CATECHIN; DAIDZEIN; GEFITINIB; GENISTEIN; GREEN TEA EXTRACT; ISOFLAVONE DERIVATIVE; LUTEINIZING HORMONE; LYCOPENE; PHYTOSTEROL; PLACEBO; POLYPHENOL DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; SELENIUM; SURAMIN;

CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CHEMOPROPHYLAXIS; DIET SUPPLEMENTATION; DIET THERAPY; DRUG DOSE COMPARISON; HUMAN; MOUSE STRAIN; NONHUMAN; PROSTATE CANCER; RANDOMIZATION; RAT STRAIN; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; TUMOR VOLUME;

CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; MUS;

EID: 38349092699     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2007.11.006     Document Type: Review

References (38)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
2. Haenszel W., and Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J. Natl. Cancer Inst. 40 (1968) 43-68
3. Stewart A.B., Lwaleed B.A., Douglas D.A., and Birch B.R. Current drug therapy for prostate cancer: an overview. Curr. Med. Chem. Anticancer Agents 5 (2005) 603-612
4. Bosland M.C. The role of estrogens in prostate carcinogenesis: a rationale for chemoprevention. Rev. Urol. 7 Suppl. 3 (2005) S4-S10
5. Goetzl M.A., and Holzbeierlein J.M. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice. Nat. Clin. Pract. Urol. 3 (2006) 422-429
6. Postma R., de Vries S.H., Roobol M.J., Wildhagen M.F., Schroder F.H., and van der Kwast T.H. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. Cancer 103 (2005) 708-716
7. Amling C.L. Biochemical failure: role for early hormonal therapy. BJU Int. 94 suppl. 3 (2004) 9-10
8. Lippman S.M., Goodman P.J., Klein E.A., et al. Designing the selenium and vitamin E cancer prevention trial (SELECT). J. Natl. Cancer Inst. 97 (2005) 94-102
9. Clark L.C., Combs G.F., and Turnbull B.W. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276 (1999) 1957-1963
10. Heinonen O.P., Albanes D., Virtamo J., Taylor P.R., Huttunen J.K., Hartman A.M., Haapakoski J., Malila N., and Rautalahti M. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J. Natl. Cancer Inst. 90 (1998) 440-446
11. Coulter I.D., Hardy M.L., Morton S.C., Hilton L.G., Tu W., Valentine D., and Shekelle P.G. Antioxidants vitamin C and vitamin E for the prevention and treatment of cancer. J. Gen. Intern. Med. 21 (2006) 735-744
12. Neill M.G., and Fleshner N.E. An update on chemoprevention strategies in prostate cancer for 2006. Curr. Opin. Urol. 16 (2006) 132-137
13. Sarkar F.H., Adsule S., Padhye S., Kulkarni S., and Li Y. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev. Med. Chem. 6 (2006) 401-407
14. Holzbeierlein J.M., McIntosh J., and Thrasher J.B. The role of soy phytoestrogens in prostate cancer. Curr. Opin. Urol. 15 (2005) 17-22
15. Yang C.S., Lambert J.D., Hou Z., Ju J., Lu G., and Hao X. Molecular targets for the cancer preventive activity of tea polyphenols. Mol. Carcinog. 45 (2006) 431-435
16. Hollman P.C., van Trijp J.M., Mengelers M.J., de Vries J.H., and Katan M.B. Bioavailability of the dietary antioxidant flavonol quercetin in man. Cancer Lett. 114 (1997) 139-140
17. Aziz M.H., Nihal M., Fu V.X., Jarrard D.F., and Ahmad N. Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3′-kinase/Akt pathway and Bcl-2 family proteins. Mol. Cancer Ther. 5 (2006) 1335-1341
18. Pathak S.K., Sharma R.A., Steward W.P., et al. Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. Eur. J. Cancer 41 (2005) 61-70
19. Siddiqui I.A., Adhami V.M., Saleem M., and Mukhtar H. Beneficial effects of tea and its polyphenols against prostate cancer. Mol. Nutr. Food Res. 50 (2006) 130-143
20. Liao S., Umekita Y., Guo J., Kokontis J.M., and Hiipakka R.A. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett. 96 (1995) 239-243
21. Gupta S., Hastak K., Ahmad N., Lewis J.S., and Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc. Natl. Acad. Sci. U.S.A 98 (2001) 10350-10355
22. Rao A.V., Ray M.R., and Rao L.G. Lycopene. Adv. Food Nutr. Res. 51 (2006) 99-164
23. Siler U., Barella L., Spitzer V., Schnorr J., Lein M., Goralczyk R., and Wertz K. Lycopene and vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model. FASEB J. 18 (2004) 1019-1021
24. Boileau T.W., Liao Z., Kim S., Lemeshow S., Erdman F.J.W., and Clinton S.K. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J. Natl. Cancer Inst. 95 (2003) 1578-1586
25. Venkateswaran V., Fleshner N.E., Sugar L.M., et al. Antioxidants block prostate cancer in lady transgenic mice. Cancer Res. 64 (2004) 5891-5896
26. Limpens J., Schröder F.H., de Ridder C.M.A., Bolder C.A., Wildhagen M.F., Obermüller-Jevic U., Krämer K., and Van Weerden W.M. Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. J Nutr. 136 (2006) 1287-1293
27. Homma Y., Kondo Y., Kaneko M., Kitamura T., Nyou W.T., Yanagisawa M., Yamamoto Y., and Kakizoe T. Promotion of carcinogenesis and oxidative stress by dietary cholesterol in rat prostate. Carcinogenesis 25 (2004) 1011-1014
28. Van Weerden W.M., De Ridder C.M.A., Verdaasdonk C.L., Romijn J.C., Van der Kwast T.H., Schröder F.H., and van Steenbrugge G.J. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am. J. Pathol. 149 (1996) 1055-1062
29. Marques R., Van Weerden W.M., Erkens-Schulze S.E., De Ridder C.M.A., Bangma C.H., and Jenster G. The human PC346 xenograft and cell line panel: a model system for prostate cancer progression. Eur. Urol. 49 (2006) 245-257
30. Kusaka N., Nasu Y., Arata R., Saika T., Tsushima T., Kraaij R., Bangma C.H., and Kumon H. Transrectal ultrasound for monitoring murine orthotopic prostate tumor. Prostate 47 (2001) 118-124
31. Kraaij R., Van Weerden W.M., De Ridder C.M.A., Gussenhoven E.J., Honkoop J., Nasu Y., and Bangma C.H. Validation of transrectal ultrasonographic volumetry for orthotopic prostate tumours in mice. Lab.Anim. 36 (2002) 165-172
32. Thalmann G.N., Sikes R.A., Chang S.M., Johnston D.A., von Eschenbach A.C., and Chung L.W. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J. Natl. Cancer Inst. 88 (1996) 794-801
33. Schröder F.H., Kranse R., Barbet N., Hop W.C., Kandra A., and Lassus M. Prostate-specific antigen: a surrogate endpoint for screening new agents against prostate cancer?. Prostate 42 (2000) 107-115
34. Limpens J., van Weerden W.M., Krämer K., Pallapies D., Obermüller-Jevic U., and Schröder F.H. Re: prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J. Natl. Cancer Inst. 96 (2004) 554 author reply 555
35. Limpens J., Schröder F.H., de Ridder D.M.A., Bolder C.A., Wildhagen M.F., Obermüller-Jevic U., Krämer K., and Van Weerden W.M. Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. J. Nutr. 136 (2006) 1287-1293
36. Limpens J., Schröder F.H., de Ridder C.M.A., Bolder C.A., Wildhagen M.F., Obermüller-Jevic U., Krämer K., and Van Weerden W.M. Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. J. Nutr. 136 (2006) 1287-1293
37. Kranse R., Dagnelie P.C., van Kemenade M.C., de Jong F.H., Blom J.H.M., Tijburg L.B.M., Weststrate J.A., and Schröder F.H. Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study. Int. J. Cancer 113 (2005) 835-840
38. Schröder F.H., Roobol M.J., Boeve E.R., de Mutsert R., Zuijdgeest-van Leeuwen S.D., Kersten I., Wildhagen M.F., and van Helvoort A. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur. Urol. 48 (2005) 922-930